Pegvisomant - Pfizer

Drug Profile

Pegvisomant - Pfizer

Alternative Names: B2036-PEG; Somavert; Trovert

Latest Information Update: 17 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genentech; Omeris
  • Developer Pfizer
  • Class Anterior pituitary hormones; Recombinant proteins
  • Mechanism of Action Somatotropin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acromegaly
  • Discontinued Cancer; Diabetic retinopathy

Most Recent Events

  • 13 Nov 2017 The Scottish Medicines Consortium accepts pegvisomant for routine use by NHS Scotland for the treatment of Acromegaly
  • 14 Jul 2017 EMA approves pegvisomant 25mg and 30mg for Acromegaly in European Union (SC) before July 2017
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top